CTDNA

This study tests whether two drugs, fruquintinib and tislelizumab, can control leftover cancer cells in people with colorectal cancer who have completed chemotherapy but still show signs of minimal residual disease (MRD) on a blood test. About 20 participants will receive the com…

This study looks at 340 people with high-risk stage II colorectal cancer who still have tumor DNA in their blood one month after surgery. Researchers want to see if using this blood test to decide on stronger chemotherapy can help clear the cancer DNA and improve survival. The go…

This study tests whether a blood test that detects tumor DNA can help doctors decide how long chemotherapy should last for people with certain types of colorectal cancer. About 340 adults with T4N0 or low-risk stage III colorectal cancer will be randomly assigned to standard 3-mo…

This study tests a new approach for people with advanced esophageal cancer that cannot be removed by surgery. Participants first receive a combination of immunotherapy and chemotherapy, followed by standard chemoradiation. Throughout treatment, doctors will monitor tiny bits of t…

This study is for people with high-risk stage III colorectal cancer. It uses a blood test (ctDNA) to see if adding a targeted drug (bevacizumab) to standard chemotherapy works better than chemo alone. About 100 participants will be randomly assigned to one of two treatment groups…

This study is for people with stage I or low-risk stage II colorectal cancer who have a positive ctDNA blood test one month after surgery, indicating a higher risk of the cancer coming back. The trial will compare different chemotherapy plans to see which one clears the ctDNA fro…

This study is testing a blood test that looks for DNA changes from cancer cells to detect biliary tract cancers (cancers of the bile ducts and gallbladder) earlier. These cancers are often found late, making them hard to treat. The test aims to improve diagnosis and help doctors …

This study explores whether a simple blood test that measures tumor DNA (ctDNA) can help doctors decide the best treatment for people with HER2-negative metastatic breast cancer. About 122 participants will first receive a standard antibody-drug combination therapy. Based on how …